Cure8

Why This Matters

Fatigue affects a large share of people with IBD and often persists despite remission; understanding treatment options and the need for a broad care plan can help patients and clinicians set realistic goals and prioritize interventions.

Who Should Pay Attention

Adults with IBD (Crohn’s disease or ulcerative colitis), clinicians treating IBD, and multidisciplinary care teams interested in symptom management and quality-of-life interventions.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This narrative review synthesizes evidence that fatigue in IBD is multifactorial — driven by inflammation but also by secondary contributors such as anaemia, psychiatric comorbidity, sleep disturbance, pain, and nutritional status.

The authors emphasize that drug therapy can help by treating active inflammation or specific secondary causes (for example correcting anaemia or treating depression), but there is limited high-quality evidence that any single pharmacological agent alone will resolve fatigue.

Management should be holistic: clinicians are encouraged to identify a patient’s dominant contributors to fatigue and address them systematically with both pharmacological and non-pharmacological strategies delivered by a multidisciplinary team. The review frames pharmacotherapy as one element within integrated care rather than a standalone solution.

Keep In Mind

This record is a narrative review (abstract-level summary provided). The authors note that the evidence base for many pharmacological approaches to fatigue is weak; the article frames recommendations as a pragmatic, multidisciplinary approach rather than definitive treatment guidelines.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationDrugs
AuthorsJai Sareen, Madelaine Prichodko, Lesley A Graff +3 more
InstitutionMax Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedOct 15, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: Declarations. Funding: This manuscript was unfunded. Dr Bernstein is supported in part by the Bingham Chair in Gastroenterology. Mr Sareen and Ms Prichodko were funded by the BSc Med Summer Research Program of the University of Manitoba Rady Faculty of Health Sciences, Max Rady College of Medicine. Conflicts of interest: Dr Charles Bernstein is supported by the Bingham Chair in Gastroenterology. Dr. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Celltrion, Eli Lilly Canada, Ferring Canada, Fresenius-Kabi Canada, JandJ Pharma Canada, Organon Canada, Pendopharm Canada, Sanofi Canada, Takeda Canada, and Pfizer Canada; Educational grants from Abbvie Canada, Boston Scientific, Celltrion, Eli Lilly Canada, Ferring Canada, Fresenius Kabi Canada, JandJ Pharma Canada, Pfizer Canada, Takeda Canada, and Speaker’s panel for Abbvie Canada, JandJ Pharma Canada, Eli Lilly, Fresenius-Kabi, Medtronic Canada, Pfizer Canada, and Takeda Canada. Received research or grant funding from Abbvie Canada, Celltrion, JandJ Pharma Canada, Pfizer Canada, and Takeda Canada. Dr Graff has received a speaker honorarium from Amgen, and investigator-initiated research from Takeda Canada and Pfizer Canada. The other authors had no conflicts to declare. Ethics approval: None was required for this narrative review. Consent to participate: None was required. Consent for publication: None was required. Availability of data and materials: All data are reported in this manuscript Code availability: Not applicable. Author contributions: Jai Sareen and Madelaine Prichodko wrote the first draft of the manuscript. Jai Sareen, Madelaine Prichodko, Lesley A. Graff, Ali Keshavarzian, Robin M Voigt, and Charles N Bernstein MD all contributed to the outline of the manuscript, to the literature review and the editing of the manuscript. AI use: The authors used generative AI tools (Claude, Anthropic; ChatGPT, OpenAI) solely to assist with language editing and refinement of wording during manuscript preparation. All literature searching, interpretation of the evidence, clinical reasoning, and conclusions are entirely the authors' own. No AI tool was used for drafting original content, data analysis, summarization of sources, translation, or image generation. The authors reviewed and edited all AI-assisted text and take full responsibility for the content of the article.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →